- Flunixin
-
- $135.00
-
2026-07-14
- CAS:38677-85-9
- Purity: 99.95%
- Supply Ability: 10g
- FLUNIXIN MEGLUMINE
-
- $1.10
-
2025-11-18
- CAS:38677-85-9
- Min. Order: 1g
- Purity: 99.00%
- Supply Ability: 100 Tons Min
- FLUNIXIN MEGLUMINE
-
- $7.00
-
2020-01-10
- CAS:38677-85-9
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 100KG
|
| | FLUNIXIN MEGLUMINE Basic information |
| | FLUNIXIN MEGLUMINE Chemical Properties |
| Melting point | 136.6-137.4 °C | | Boiling point | 378.7±42.0 °C(Predicted) | | density | 1.403±0.06 g/cm3(Predicted) | | solubility | H2O: freely soluble | | pka | 5.82(at 25℃) | | form | solid | | color | off-white | | Stability: | Stable. Incompatible with strong bases, strong oxidizing agents. | | Major Application | forensics and toxicology
pharmaceutical (small molecule) | | InChI | 1S/C14H11F3N2O2/c1-8-10(14(15,16)17)5-2-6-11(8)19-12-9(13(20)21)4-3-7-18-12/h2-7H,1H3,(H,18,19)(H,20,21) | | InChIKey | NOOCSNJCXJYGPE-UHFFFAOYSA-N | | SMILES | Cc1c(Nc2ncccc2C(O)=O)cccc1C(F)(F)F | | CAS DataBase Reference | 38677-85-9(CAS DataBase Reference) | | EPA Substance Registry System | 3-Pyridinecarboxylic acid, 2-[[2-methyl-3-(trifluoromethyl)phenyl]amino]- (38677-85-9) |
| Hazard Codes | Xi,Xn | | Risk Statements | 36/37/38-22 | | Safety Statements | 26-36 | | RIDADR | UN2811 6.1/PG 3 | | WGK Germany | 3 | | RTECS | LZ4367000 | | HS Code | 2933399990 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 3 Oral |
| | FLUNIXIN MEGLUMINE Usage And Synthesis |
| Chemical Properties | Crystalline Solid | | Uses | Cyclooxigenase inhibitor. Anti-inflammatory; analgesic; antipyretic | | Definition | ChEBI: A pyridinemonocarboxylic acid that is nicotinic acid substituted at position 2 by a 2-methyl-3-(trifluoromethyl)phenylamino group. A relatively potent non-narcotic, nonsteroidal analgesic with anti-inflammatory, anti-endotoxic and anti-pyretic properties;
sed in veterinary medicine (usually as the meglumine salt) for treatment of horses, cattle and pigs. | | General Description | Flunixin is classified under the group of non-steroidal anti-inflammatory drugs (NSAIDs). | | in vivo | Flunixin meglumine (intravenous injection; 1.1 mg/kg; once) treatment inhibits the formation of exudate PGE2 and serum TXB2[1]. | Animal Model: | Male sheep injected with Carrageenan[1] | | Dosage: | 1.1 mg/kg | | Administration: | Intravenous injection; 1.1 mg/kg; once | | Result: | Inhibited Carrageenan-induced exudate PGE2 formation (Emax, 100%, IC50, <0.4 nM) and serum TXB2 generation (Emax, 100%, IC50, 17 nM) for up to 32 h. |
| | IC 50 | COX-1: 0.55 μM (IC50); COX-2: 3.24 μM (IC50) |
| | FLUNIXIN MEGLUMINE Preparation Products And Raw materials |
|